文献速递炎症性肠病

炎症性肠病患者合并免疫介导疾病:一项全国性基于人群的研究

Comorbid immune-mediated diseases in inflammatory bowel disease: a nation-wide population-based study.
PubMed 文献 · Aliment Pharmacol Ther · 2018-12-02

该研究利用韩国全民健康保险理赔数据,纳入2012至2013年35 581例无免疫介导疾病的炎症性肠病患者和595例合并免疫介导疾病的患者,随访至2016年,并按年龄和性别匹配对照。结果显示炎症性肠病患者免疫介导疾病总体风险升高(HR 2.47,95%CI 2.09-2.91),5-氨基水杨酸使用可能降低该风险(OR 0.61,95%CI 0.41-0.90),合并免疫介导疾病与需要抗TNF-α药物及急性发作风险增加相关。

要点

  • 炎症性肠病患者免疫介导疾病总体风险高于非炎症性肠病人群(HR 2.47,95%CI 2.09-2.91)。
  • 5-氨基水杨酸使用对发生免疫介导疾病有保护作用(OR 0.61,95%CI 0.41-0.90)。
  • 合并免疫介导疾病增加需要抗TNF-α药物(HR 2.40)和急性发作(HR 1.76)风险。

核心结论

  • 炎症性肠病患者免疫介导疾病发生率高于非炎症性肠病人群,5-氨基水杨酸使用可能降低该风险。

研究设计与样本

  • 利用韩国全民健康保险理赔数据,纳入2012至2013年35 581例无免疫介导疾病的炎症性肠病患者和595例合并免疫介导疾病的炎症性肠病患者,随访至2016年,并按年龄和性别匹配对照。
  • 从2014至2016年随访35 581例无免疫介导疾病的炎症性肠病患者和142 324例匹配对照,其中239例炎症性肠病患者和357例对照发生免疫介导疾病。
  • 在炎症性肠病队列中进行巢式病例对照研究,分析新发免疫介导疾病的危险因素。

主要发现

  • 炎症性肠病患者免疫介导疾病总体风险升高(HR 2.47,95%CI 2.09-2.91)。
  • 在炎症性肠病队列的巢式病例对照研究中,年龄≥20岁的成年患者和每年住院≥1次是新发免疫介导疾病的独立危险因素。
  • 5-氨基水杨酸使用对发生免疫介导疾病有保护作用(OR 0.61,95%CI 0.41-0.90)。
  • 合并其他免疫介导疾病的炎症性肠病患者需要抗TNF-α药物的风险增加(HR 2.40,95%CI 2.02-2.84)。
  • 合并其他免疫介导疾病的炎症性肠病患者发生急性发作的风险增加(HR 1.76,95%CI 1.37-2.26)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Although a higher risk of other immune-mediated diseases has been reported in inflammatory bowel disease (IBD) patients, the risk factors of immune-mediated diseases development and the effect of concomitant immune-mediated diseases on outcomes remain poorly defined. AIM: To determine the risk factors of incident immune-mediated diseases and the impact of comorbid immune-mediated diseases on outcomes in IBD. METHODS: Using the National Health Insurance claims data for the entire Korean population, we identified 35 581 IBD patients without immune-mediated diseases and 595 IBD patients with immune-mediated diseases from 2012 to 2013, and follow-up until 2016. We selected four controls by age and sex for comparing with cases. RESULTS: A total of 35 581 IBD patients without immune-mediated diseases and 142 324 matched controls without immune-mediated diseases were followed from 2014 to 2016 and of these 239 IBD patients and 357 controls developed immune-mediated disease. The overall immune-mediated diseases risk was higher in IBD patients (HR, hazard ratio, 2.47; 95% confidence interval, CI, 2.09-2.91). In a nested case-control study of the IBD cohort, adult patients aged ≥20 years and frequent hospitalisation ≥1 per year were independent risk factors for incident immune-mediated diseases, in contrast, 5-aminosalicylic acid (5-ASA) use had protective effect (odds ratio, 0.61; 95% CI, 0.41-0.90) for developing immune-mediated diseases. In addition, IBD patients with another immune-mediated disease had an increased risk of needing anti-TNF-α agent (HR, 2.40; 95% CI, 2.02-2.84) and developing acute flare (HR, 1.76; 95% CI, 1.37-2.26). CONCLUSIONS: The incidence of immune-mediated diseases in IBD patients was higher than that of non-IBD population. 5-ASA use may reduce this risk.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Park SW, Kim TJ, Lee JY, et al. Comorbid immune-mediated diseases in inflammatory bowel disease: a nation-wide population-based study. Aliment Pharmacol Ther. 2018. PMID: 30506945. doi:10.1111/apt.15076

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。